Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025α7 nicotinic ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio ® is a ...

Nanoelectronics specialist Imec will demonstrate a miniaturised, ingestible sensor device today that can monitor ...

The 5th Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) will gather industry leaders in Vösendorf, Austria on ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

Shares of 3SBio jumped as much as 52% in Hong Kong, the most on record, extending gains for the third consecutive session.